Ascendis Pharma AS ADR (ASND)
Ascendis Pharma A/S is a biopharmaceutical company focused on TransCon-based therapies for unmet medical needs in Europe, the United States, and other international markets. The company’s approved products include SKYTROFA, used in pediatric patients with growth hormone deficiency, and YORVIPATH, a once-daily subcutaneous treatment for adults with chronic hypoparathyroidism. In addition to its commercial portfolio, Ascendis Pharma is advancing a pipeline that includes three independent endocrinology rare disease candidates in clinical development, while also pursuing oncology programs. The listed security is an ADR representing Ascendis Pharma A/S on NASDAQ under the symbol ASND. Founded in 2006, the company is based in Hellerup, Denmark.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ASND
|
$277.64
|
0.8% Upside
|
Fair
|
$307.64
|
11.7% Upside
|
Fair
|
Great
|
0.0%
|
February 17, 2027
|
18.1x
|
10.6x
|
13.2x
|
18.064 B
|
17.402 B
|
2.7%
|
100.0%
|
8.8
|
59.2%
|